clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with clarithromycin
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Vakil N | Helicobacter pylori treatment: is sequential or quadruple therapy the answer? | 2008 | Rev Gastroenterol Disord | pmid:18641590 |
Carabias ML et al. | [Are the antimicrobials used in community-acquired respiratory infection useful for preventing transmission of meningococcal disease? In vitro study]. | 2001 | Rev Esp Quimioter | pmid:11704772 |
Gordillo RM et al. | [Susceptibility of Streptococcus pyogenes isolates from pharyngeal exudates in Cordoba (Spain)]. | 2003 | Rev Esp Quimioter | pmid:12750758 |
Cantón E et al. | [In vitro susceptibility to antibiotics and the most common Streptococcus pneumoniae serotypes: a multicenter study]. | 2005 | Rev Esp Quimioter | pmid:15915232 |
Agudo S et al. | Rapid detection of clarithromycin resistant Helicobacter pylori strains in Spanish patients by polymerase chain reaction-restriction fragment length polymorphism. | 2011 | Rev Esp Quimioter | pmid:21412667 |
DÃaz-Reganon J et al. | [Susceptibility of 36 Helicobacter pylori clinical isolates to four first-line antibiotics and virulence factors]. | 2006 | Rev Esp Quimioter | pmid:16688289 |
Agudo S et al. | [High percentage of clarithromycin and metronidazole resistance in Helicobacter pylori clinical isolates obtained from Spanish children]. | 2009 | Rev Esp Quimioter | pmid:19544100 |
Orellana MA and Gómez-Lus ML | [Which is the best empirical treatment in patients with urethritis?]. | 2011 | Rev Esp Quimioter | pmid:21947096 |
Vega AE et al. | [Detection of resistance to clarithromycin in clinical isolates of Helicobacter pylori from children and adults]. | 2003 | Rev Esp Quimioter | pmid:12750757 |
Ruiz-Aragón J et al. | [Susceptibility to antimicrobial agents of rapidly growing mycobacteria]. | 2007 | Rev Esp Quimioter | pmid:18563216 |
Guirao-Arrabal E et al. | Clarithromycin plus linezolid as a sequential therapy for implantable-cardioverter-defibrillator infection caused by coagulase-negative staphylococci. | 2016 | Rev Esp Quimioter | pmid:26888341 |
Miglietta F et al. | A rare case of Saprochaete capitata fungemia in a critical ill patient without hematologic and oncological disorders. | 2016 | Rev Esp Quimioter | pmid:26785226 |
Gálvez-Múgica MA et al. | [Meta-analysis of clarithromycin compared to other antibiotics for the treatment of lower respiratory tract infections]. | 2003 | Rev Esp Quimioter | pmid:14961134 |
Alarcón T et al. | [In vitro activity of clarithromycin and metronidazole against Helicobacter pylori in different incubation atmospheres]. | 2002 | Rev Esp Quimioter | pmid:12587039 |
Rubio-Terrés C et al. | [Pharmacoeconomic analysis of community-acquired pneumonia treatment with telithromycin or clarithromycin]. | 2003 | Rev Esp Quimioter | pmid:14702121 |
Abad-Santos F et al. | [Meta-analysis of clarithromycin compared with other antimicrobial drugs in the treatment of upper respiratory tract infections]. | 2003 | Rev Esp Quimioter | pmid:14702124 |
Alarcón T et al. | [In vitro activity of furazolidone and nitrofurantoin in Helicobacter pylori clinical isolates and study of mutation rate]. | 2005 | Rev Esp Quimioter | pmid:16446791 |
Abasolo Osinaga E et al. | [Dispensation and cost of antimicrobials in Spain (1998-2000)]. | 2005 | Rev Esp Quimioter | pmid:16446789 |
Orden MartÃnez B et al. | [Haemophilus spp. antimicrobial susceptibility in Health Area 6 in Madrid, Spain (2000-2004)]. | 2005 | Rev Esp Quimioter | pmid:16130040 |
Garza González E et al. | [Helicobacter pylori erradication and its relation to antibiotic resistance and CYP2C19 status]. | 2007 | Rev Esp Enferm Dig | pmid:17417917 |
de Artaza Varasa T et al. | [Effect of Helicobacter pylori eradication on patients with functional dyspepsia]. | 2008 | Rev Esp Enferm Dig | pmid:19025303 |
Gisbert JP et al. | [What is the current role of clarithromycin in the eradication of Helicobacter pylori?]. | 1997 | Rev Esp Enferm Dig | pmid:9221019 |
Rodrigo Sáez L et al. | [The efficacy of using a short course of 6-day duration (OCA-6) in the treatment to eradicate Helicobacter pylori infection. Omeprazole, clarithromycin, amoxicillin]. | 1997 | Rev Esp Enferm Dig | pmid:9115827 |
Sainz R et al. | [Helicobacter pylori infection. The Spanish consensus report. The Spanish Consensus Conference Group]. | 1999 | Rev Esp Enferm Dig | pmid:10601771 |
Rojas Feria M et al. | Resistance of Helicobacter pylori to antimicrobial treatment in a Seville hospital catchment area. | 2000 | Rev Esp Enferm Dig | pmid:11468787 |
RodrÃguez Téllez M et al. | Morphometric estimation of acid output in duodenal ulcer associated with Helicobacter pylori infection. | 1999 | Rev Esp Enferm Dig | pmid:10491487 |
Gisbert JP | [Lansoprazole: a review of its role in Helicobacter pylori eradication therapy]. | 1999 | Rev Esp Enferm Dig | pmid:10231305 |
González Carro P et al. | [Efficacy of an ultrashort protocol in the eradication of Helicobacter pylori]. | 1998 | Rev Esp Enferm Dig | pmid:9780793 |
Boixeda D et al. | Seven-day proton pump inhibitor, amoxicillin and clarithromycin triple therapy. factors that influence Helicobacter pylori eradications success. | 2003 | Rev Esp Enferm Dig | pmid:12760710 |
Gisbert JP et al. | Validation of the 13c-urea breath test for the initial diagnosis of helicobacter pylori infection and to confirm eradication after treatment. | 2003 | Rev Esp Enferm Dig | pmid:12760719 |
Torres-Debat ME et al. | Antimicrobial susceptibility of Helicobacter pylori and mechanisms of clarithromycin resistance in strains isolated from patients in Uruguay. | 2009 | Rev Esp Enferm Dig | pmid:20001152 |
Boixeda de Miquel D | [Efficacy of the triple therapy in the eradication of H. pylori in peptic ulcer]. | 1997 | Rev Esp Enferm Dig | pmid:9494374 |
Pérez Mota A et al. | Helicobacter pylori, efficacy of the new triple therapy in six and twelve-day schedules. | 1997 | Rev Esp Enferm Dig | pmid:9494375 |
Castro-Fernández M et al. | Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori. | 2009 | Rev Esp Enferm Dig | pmid:19630462 |
Fernández Martos R et al. | Acute psychotic episode secondary to Helicobacter pylori eradication treatment. | 2017 | Rev Esp Enferm Dig | pmid:28071063 |
Murcia J et al. | [Acute myocardial failure in a young man: Q-fever myocarditis]. | 2002 | Rev Esp Cardiol | pmid:12199986 |
Vallejo Camazón N et al. | [Ventricular tachycardia and long QT associated with clarithromycin administration in a patient with HIV infection]. | 2002 | Rev Esp Cardiol | pmid:12199987 |
Olmos MartÃnez JM et al. | [Definitive treatment of Helicobacter pylori infection in MALT low degree gastric lymphoma]. | 2003 | Rev Clin Esp | pmid:14622518 |
Alba D et al. | [Clarithromycin in the treatment of cerebral toxoplasmosis associated with HIV infection]. | 1993 | Rev Clin Esp | pmid:8516514 |
DÃaz F et al. | [Cat-scratch disease. A report of 4 cases and a review of the literature]. | 1997 | Rev Clin Esp | pmid:9102668 |
Baena DÃez JM et al. | [Are 5 days of omeprazole plus 2 antibiotics enough for eradication of H. pylori? Comments on sample size]. | 1999 | Rev Clin Esp | pmid:10432821 |
Gisbert JP et al. | [Omeprazole plus 2 antibiotics for the eradication of H. pylori, are 5 days of treatment sufficient?]. | 1998 | Rev Clin Esp | pmid:9844453 |
Gisbert JP et al. | [Role of pantoprazole in the eradicating treatment of Helicobacter pylori]. | 1998 | Rev Clin Esp | pmid:9844458 |
Asencio Marchante R and Lissen Otero E | [Secondary prevention of opportunistic infections in HIV-infected patients]. | 2001 | Rev Clin Esp | pmid:11345612 |
Cofré Guerra J | [Pertussis chemoprophylaxis: a sterile effort?]. | 2006 | Rev Chilena Infectol | pmid:16462967 |
MorfÃn Maciel BM and Castillo Ramos HA | [Reactive polyarthritis and painful dermatographism caused by Helicobacter pylori]. | 2002 May-Jun | Rev Alerg Mex | pmid:12190006 |
Matieli LC et al. | Mycobacterium abscessus endophthalmitis: treatment dilemma and review of the literature. | 2006 | Retina (Philadelphia, Pa.) | pmid:16963860 |
Unal M et al. | Ocular toxicity of intravitreal clarithromycin. | 1999 | Retina (Philadelphia, Pa.) | pmid:10546942 |
Ding FM et al. | Low-dose clarithromycin therapy modulates CD4(+) T-cell responses in a mouse model of chronic Pseudomonas aeruginosa lung infection. | 2012 | Respirology | pmid:22404374 |
Kikuchi E et al. | Pharmacokinetics of clarithromycin in bronchial epithelial lining fluid. | 2008 | Respirology | pmid:18339019 |